Delivery Order SPE2DB22D3016-SPE2DB24FBGB7

Award Date 9/5/24
Potential Completion Date 9/6/24
Potential Value $17K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Activase 100 mg vials. The contract has a ceiling value of $23,488.81 and a completion date of February 8, 2023. It is a firm-fixed-price contract type. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This is a Delivery Order contract awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for $7,778.45. The contract is for the delivery of ACTIVASE 50 MG VIALS, a medical product, with a completion date of June 4, 2025. The contract is a Firm Fixed Price type and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued...
This is a $14,164.76 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp. The contract is for the supply of 100 mg vials of the pharmaceutical product ACTIVASE. This delivery order was issued under a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that AmerisourceBergen holds with DLA Troop Support Medical for the provision of a comprehensive range of medical commodities to support military treatment programs and...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $2,864.71 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of 50 mg vials of the pharmaceutical Activase. This award is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00, which serves as the primary contract vehicle for Amerisourcebergen to deliver pharmaceutical products and medical supplies to DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $14,839.85, is for the delivery of 4,567,962,457 units of ACTIVASE 50 MG VIALS, a medication used for medical treatment. The contract is a firm fixed-price, non-set-aside award with an ultimate completion date of April 21, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $27,192.05 firm fixed-price delivery order is for the supply of 100 mg vials of the drug Activase, with a period of performance through November 13, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,037.09, is for the provision of 4564463004 ACTIVASE 100 MG VIALS, a specialty pharmaceutical product. The contract has a firm fixed price and an ultimate completion date of May 2, 2024. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a $8,903.91 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of ACTIVASE 50 MG VIALS. The contract has a completion date of June 23, 2025 and is not set aside. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through December...
This is a delivery order under a prime contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The delivery order is for the supply of 100 mg vials of the drug Activase, a critical medical product used in emergency care. The award has a ceiling value of $14,852.25 and a completion date of August 16, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,974.16 firm fixed-price delivery order contract is for the supply of 50 mg vials of the drug Activase. The contract has an ultimate completion date of April 10, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary...
  • SPE2DB22D3016
    Indefinite Delivery Contract
  • SPE2DB22D3016-SPE2DB24FBGB7
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor, for the supply of Activase 100 mg vials. The contract has a firm fixed price of $17,103.37 and a completion date of September 6, 2024. Amerisourcebergen has been awarded this delivery order as part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. This contract does not have a set-aside designation.

Generated 12/5/24, 9:46 AM